MeiraGTx Secures $400M from Oberland for AAV2-hAQP1 and Bota-vec
MGTX•MeiraGTx secured a $400 million strategic investment from Oberland Capital, comprising $375 million in non-dilutive royalty funding and $25 million in equity to advance AAV2-hAQP1, botaretigene sparoparvovec and AAV-AIPL1 programs. The initial $135 million tranche includes $125 million for capped low single-digit royalties and a $10 million equity infusion.
1. Strategic Investment Details
MeiraGTx entered a $400 million agreement with Oberland Capital, receiving up to $375 million in non-dilutive royalty funding and $25 million in equity. The company drew an initial $135 million, split into $125 million for capped low single-digit royalties and a $10 million equity injection.
2. Milestone-Based Tranches
Additional funding tranches include $50 million at MeiraGTx’s option upon positive Phase 2 AQUAx2 data in 2027, $50 million upon bota-vec regulatory approval in 2027, $50 million upon AAV2-hAQP1 approval in 2028, plus $100 million for new products or business development and a $15 million equity purchase right for Oberland.
3. Targeted Therapies and Royalties
The deal covers three late-stage gene therapies: AAV2-hAQP1 for grade 2/3 radiation-induced xerostomia, botaretigene sparoparvovec for X-linked retinitis pigmentosa and AAV-AIPL1 for LCA4. Royalty payments are capped at a multiple of funded amounts, with low single-digit rates on each product’s net sales.
4. Commercialization and Financial Flexibility
Oberland’s investment supports global launch preparations while preserving MeiraGTx’s business development flexibility. The agreement allows MeiraGTx to repay or buy back the royalty note under specified conditions, maintaining control over future strategic opportunities.
